Patient Reported Outcomes in a Practice Changing Randomized Trial of Bevacizumab in the Treatment of Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study

BACKGROUND: To analyze patient reported outcomes (PROs) in GOG 240, the practice-changing, randomized phase 3 trial that concluded that chemotherapy (cisplatin-paclitaxel or topotecan-paclitaxel) plus bevacizumab significantly improves overall survival (OS), progression-free survival (PFS), and resp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Penson, Richard T., Huang, Helen Q., Wenzel, Lari B., Monk, Bradley J., Stockman, Sharon, Long, Harry J., Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J.A., Leitao, Mario M., Method, Michael, Michael, Helen, Tewari, Krishnansu S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4479218/
https://ncbi.nlm.nih.gov/pubmed/25638326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)70004-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados